Coronary revascularization in patients with coronary artery disease and chronic kidney disease

被引：2

作者：

Keeley, EC

McCullough, PA

机构：

[1] Univ Texas, SW Med Ctr, Div Cardiol, Dept Internal Med, Dallas, TX 75390 USA

[2] William Beaumont Hosp, Dept Med, Div Cardiol, Royal Oak, MI 48072 USA

[3] William Beaumont Hosp, Dept Med, Div Nutr, Royal Oak, MI 48072 USA

[4] William Beaumont Hosp, Dept Med, Dept Prevent Med, Royal Oak, MI 48072 USA

来源：

ADVANCES IN CHRONIC KIDNEY DISEASE | 2004年 / 11卷 / 03期

关键词：

chronic kidney disease; percutaneous coronary intervention; coronary artery bypass surgery;

D O I：

10.1053/j.arrt.2004.04.007

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

There is a remarkable lack of randomized trial data on optimal management of coronary artery disease (CAD) in patients with chronic kidney disease (CKD). In fact, patients with CKD are often excluded from randomized trials that compare different treatment strategies for CAD. Because the most common cause of death in CKD patients is cardiovascular disease, it is crucial that studies are designed to determine the best therapy for CAD in this high-risk group. This article discusses the available data on coronary revascularization outcomes in CKD patients. (C) 2004 by the National Kidney Foundation, Inc.

引用

页码：254 / 260

页数：7

共 42 条

[21]

Liu JY, 2000, CIRCULATION, V102, P2973

[22] Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations [J].